Evidence map›Paper›PMID 40832357›Full record

ArticlebioRxiv : the preprint server for biology2025

Human Stem Cell-Derived β-cells Expressing An Optimized CD155 Reduce Cytotoxic Immune Cell Function for Application in Type 1 Diabetes.

Matthew E Brown, Jessie M Barra, Marcus R Pina, James Proia, Todd M Brusko, Holger A Russ

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Matthew E BrownDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-8230-5243
Jessie M BarraDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-6456-9293
Marcus R PinaDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0009-0002-2180-2531
James ProiaDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0009-0004-5454-9821
Todd M BruskoDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-2878-9296
Holger A RussDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-5117-2927

Funding

Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9M
The CD226 costimulatory axis in type 1 diabetesR01DK106191 · NIDDK · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 2016 to 2026
$4.4M
Local immune modulation for beta cell replacement therapy in type 1 diabetesR01DK132387 · NIDDK · UNIVERSITY OF FLORIDA · PI PHELPS, EDWARD, RUSS, HOLGER A. · 2022 to 2025
$2.1M
NIAID NIH HHS P01 AI042288NIDDK NIH HHS R01 DK106191NIDDK NIH HHS R01 DK132387
6 · The paper itself

Abstract

Insulin-producing β-cell replacement therapies offers a potential treatment for type 1 diabetes (T1D) but faces challenges from donor shortages and immune rejection. Stem cell-derived β-cells (sBC) provide a renewable source but remain vulnerable to immune attack. We engineered human pluripotent stem cells to express either the wildtype (WT) or a high-affinity mutant (Mut) variant (rs1058402, G>A; Ala67Thr) of the NK and T cell checkpoint inhibitor CD155 before differentiation into sBC. Modified sBC maintained upregulated CD155 expression and showed enhanced binding to co-receptor ligands. Co-culture studies revealed that CD155 Mut-expressing sBC suppressed CD8

Indexed as

autoimmunityCD155stem cell-derived β-like cellTIGITType 1 diabetes

Identifiers

PMID40832357
PMCPMC12363821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.